Brooke Nesmith, MD
Retina Specialist · Wichita, KSNPI 1295020667
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $4,574 of the $5,711 with a category attached, or 80.1%. US Retina LLC accounts for 80.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $2,455 and has fallen 97.2% since, to $70 in 2025.
Across 49 payments — averaging $116.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$5K
- AbbVie$286
- Genentech USA, Inc.$265
- Amgen$88
- Alimera Sciences, Inc.$88
- Novartis$76
- plus $334 from 9 others
What the payments were for
- Food & beverage$1,13720%
- Ownership interest$4,57480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 3 | $4,574 |
| AbbVie(2 entities) | 9 | $286 |
| Genentech USA, Inc. | 9 | $265 |
| Amgen(2 entities) | 5 | $88 |
| Alimera Sciences, Inc. | 4 | $88 |
| Novartis | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Glaukos Corporation | 1 | $70 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $61 |
| Mallinckrodt Enterprises LLC | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Bausch & Lomb Americas Inc. | 1 | $15 |
| Topcon Healthcare, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 119 | $3,264 |
| Ofloxacin | 72 | $818 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $516 |
| Latanoprost | 37 | $241 |
| Dorzolamide Hcl | 14 | $160 |
| Brimonidine Tartrate | 36 | $100 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Wichita
- Paul WeishaarWichita$17K
- Kumar DallaWichita$14K
- Michael VarenhorstWichita$10K
- David ChackoWichita$8K
- Alan HromasWichita$3K
- Thomas WoltjerWichita$2K
- Charles BeckWichita$298
- Javed SayedLeawood$8K
- Mary ChampionPrairie Village$3K
- Radwan AjlanKansas City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.